CGEM - NASDAQ

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%

HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$934.78M

EPS-3.7200

P/E Ratio-4.09

Earnings Date08/06/2026

cgem

Property, Plant, and Equipment (Net)

Last Annual Value

3.05M

3-Year CAGR

-17%

5-Year CAGR

88%

10-Year CAGR

29%

Adjust for Inflation

Cullinan Therapeutics, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

CGEM · NASDAQ

Company	Property, Plant, and Equipment (Net)	CAGR 3Y	CAGR 5Y	CAGR 10Y
Cullinan Therapeutics, Inc. NASDAQ:CGEM	3.05M	-4.8%	108.7%	N/A
Varex Imaging Corporation NASDAQ:VREX	187.20M	2.7%	2.6%	N/A
CeriBell, Inc. NASDAQ:CBLL	4.33M	5.0%	N/A	N/A
Enhabit, Inc. NYSE:EHAB	65.30M	-5.1%	-1.0%	N/A
Standard BioTools Inc. NASDAQ:LAB	46.01M	-5.7%	-6.7%	10.8%
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	457.00K	-59.5%	-35.3%	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	4.70M	-15.1%	11.4%	N/A
Omeros Corporation NASDAQ:OMER	12.48M	-15.4%	-16.1%	26.6%

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $15.21

Related Guides

Blog Categories

Continue your CGEM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.